• Press
  • Offices
  • Contact
  • Legal notice
  • LinkedIn
  • EN
    • DE
  • UPC
  • Firm
    • Main Focus
    • History
    • Guiding Principle
    • Code of Conduct
    • Awards and Rankings
  • Our Practice
    • Legal Areas
    • Industries
  • Our Team
  • News & Events
    • News
    • Events
    • UPC-Update
    • IP-Update
    • Publications
  • Career
  • Menu Menu
FIND EXPERTS
  • UPC
  • Firm
  • News & Events
    • News
    • Events
    • UPC-Update
    • IP-Update
    • Publications
    • B&B Bulletin
  • FIND EXPERTS
  • Contact
  • Our Practice
  • Career
  • Offices
  • EN
    • DE
  • Legal Areas
  • Industries

B&B Partners obtain patentee-friendly decisions from the Boards of Appeal of the European Patent Office

30. October 2024/in IP-Update, Issue November 2024 Patents and Utility Models

Rule 80 EPC – Multiple independent claims for defending a patent in opposition proceedings

Within a short period of time, the Boards of Appeal of the European Patent Office have issued two parallel decisions that were obtained by partners of BOEHMERT & BOEHMERT in favour of our clients. Both decisions were published on 14 October 2024 and in both cases the interesting legal question is whether R. 80 EPC precludes the limited defence of a European patent in opposition proceedings with a set of claims that, instead of an independent claim of the granted patent, contains several independent claims that constitute different limitations of the independent claim of the granted patent.

Appeal T0123/22 – several independent claims limited by different features from the description

In the appeal case T0123/22, patent attorney Dr. Daniel Herrmann succeeded in setting aside the first-instance decision of the Opposition Division, according to which European Patent EP 2822613 B1 was revoked on the basis of R. 80 EPC. The Opposition Division had wrongly assumed that R. 80 EPC precluded a defence of the patent in a limited version by replacing an independent claim of the granted version with several independent claims, each containing different features from the description for the purpose of limitation. This decision was set aside by the Board of Appeal in a decision containing a catchword and remitted to the Opposition Division.

The Board of Appeal first clarified that R. 80 EPC is a purely substantive norm concerning the allowability of an amendment in opposition proceedings. According to the Board, the only relevant factor in assessing the requirement of R. 80 EPC is whether the amendment made is occasioned by a ground for opposition. In this regard, it was necessary to examine whether the amendment should be considered a genuine attempt to address a ground for opposition. In doing so, the board referred to the cited decision T0750/11. The circumstances of the individual case had to be taken into account. In the headnote and reasons, the board emphasised that R. 80 EPC does not provide any general guidelines as to how a patent proprietor may amend claims and, in particular, that it is irrelevant for R. 80 EPC whether the features additionally included in an attacked claim originate from dependent claims or from the description. In the present case, all three independent claims had been limited in relation to the opposed and not further pursued independent claim of the granted version and therefore apparently served to overcome the ground for opposition in the respective claim – and thus also overall. Therefore, R.80 EPC was fulfilled in the present case. According to the board, it is generally legitimate to cover several sub-areas at the same time that, in the opinion of the patent proprietor, are not affected by the ground for opposition. The purpose of R 80 EPC is not to prevent the patent proprietor from maintaining the patent as broadly as possible, taking into account the grounds for opposition.

Appeal case T1191/22 – several independent claims limited by different dependent claims

In the case T1191/22, patent attorney Felix Hermann succeeds in having the first-instance decision set aside, which had rejected an auxiliary request as contrary to R. 80 EPC because, in addition to an amended claim 1, it included further independent claims 12 to 15 based on granted dependent claims.

In line with decision T0123/22, the board corrected the opposition division’s decision by stating that R. 80 EPC is a substantive rule and not a procedural one. Referring to the earlier decision T0937/00, the board ruled that defending the patent with several parallel independent claims is in principle admissible and does not violate R. 80 EPC if the formulation of new independent claims in the opposition proceedings is aimed at overcoming asserted grounds for opposition.

Furthermore, the board stated that procedural aspects of allowability such as the lack of convergence of the independent claims or the effect of the auxiliary request on procedural economy are not relevant for the assessment of allowability under R. 80 EPC. The Board of Appeal decides to set aside the decision of the Opposition Division and to maintain the patent on the basis of the auxiliary request not admitted at first instance.

Extended scope of action for patent proprietors

The two decisions T0123/22 and T1191/22 both emphasise the substantive aspect of R. 80 EPC and distinguish it from procedural issues concerning the admissibility of a request. Both decisions, which were issued by two different boards of appeal, also confirm the principle that R. 80 EPC does not preclude a replacement of an independent claim of a granted patent with several amended independent claims in order to defend the patent in limited form, as long as the amendments can be considered a serious attempt to overcome the asserted grounds for opposition. This basically recognises the right of patent proprietors under R. 80 EPC to cover several sub-areas of the original subject-matter at the same time, i.e. in one and the same request, which from the point of view of the patent proprietors are not affected by the grounds for opposition asserted in the opposition proceedings.

 

/wp-content/uploads/2022/04/boehmert_logo.svg 0 0 Petra Hettenkofer /wp-content/uploads/2022/04/boehmert_logo.svg Petra Hettenkofer2024-10-30 10:04:262025-01-30 13:56:31B&B Partners obtain patentee-friendly decisions from the Boards of Appeal of the European Patent Office

The Trademark Lawyer 2024: BOEHMERT & BOEHMERT once again among the top law firms

28. October 2024/in Awards & Rankings

The law firm is once again listed among the ten best law firms for trademark law.

“Most well-respected law firm” is once again the verdict of the jury of the specialist magazine ‘The Trademark Lawyer’ for BOEHMERT & BOEHMERT. Alongside nine other law firms, the trademark law team can also look forward to receiving this award in 2024.

The ranking is published annually in the fall under the title “A comprehensive list of the 10 most well-respected law firms from the UK & Europe”. The criteria used by the jury to select the top 10 law firms for trademark law in each country include expertise, positive peer reviews, market profile, alternative industry rankings and feedback from readers, clients and the assessment of the international publishing network.

“The Trademark Lawyer Magazine” is published every two months in print and electronically and is an indispensable publication for all trademark lawyers worldwide. With a reach of around 30,000 per issue, the magazine claims to be aimed at in-house and private trademark lawyers as well as IP associations and C-suite executives.

The “law firm rankings” can be found online here.

/wp-content/uploads/2022/04/boehmert_logo.svg 0 0 Petra Hettenkofer /wp-content/uploads/2022/04/boehmert_logo.svg Petra Hettenkofer2024-10-28 09:00:002024-10-29 13:51:49The Trademark Lawyer 2024: BOEHMERT & BOEHMERT once again among the top law firms
Dr. Ute Kilger, Patent Attorney at BOEHMERT & BOEHMERT

Dr. Ute Kilger investi­gates the Aplidin® case in the Euro­pean Bio­techno­logy Magazine

20. October 2024/in Publications

Topic of the article: Aplidin® – a politically motivated scandal? Dr. Ute Kilger sheds light on the EMA failure and the political intervention in the Aplidin® case.

In the autumn issue of the European Biotechnology Magazine, BOEHMERT & BOEHMERT patent attorney and partner Dr. Ute Kilger examines the questionable refusal of the European Medicines Agency (EMA) to allow the Spanish biotech company PharmaMAR to market the cancer drug Aplidin®.The EMA scientific advisory group, which included an expert with a demonstrable conflict of interest, had denied the safety and efficacy of the drug.

The biotech company filed an appeal against this rejection with the European Court of Justice in October 2018. This was upheld in full in 2020. Estonia and Germany then appealed against the court’s decision, followed by the Netherlands and the EU. An unusual political move that remains a mystery. Dr. Ute Kilger raises the question of how the EMA intends to guarantee the impartiality of its experts in the future and how to deal with the damage caused to PharmaMAR by seven years of litigation and lost ROI.

The experienced patent attorney also highlights the fact that the approval figures for cancer drugs appear to be falling in Europe, while they are stagnating in the USA and rising sharply in China. This leads to the assumption that the requirements in Europe are too strict compared to other countries or that there is too much bureaucracy. She concludes that Europe does not appear to be the first port of call for new cancer drugs.

Subscribers can find the full article in the European Biotechnology Magazine Vol 23/2024 on page 36.

https://www.boehmert.de/wp-content/uploads/2022/06/Kilger-Ute-Portrait-Web.jpg 667 1000 Lucia Biehl /wp-content/uploads/2022/04/boehmert_logo.svg Lucia Biehl2024-10-20 15:26:052024-12-03 15:28:53Dr. Ute Kilger investi­gates the Aplidin® case in the Euro­pean Bio­techno­logy Magazine

Four BOEHMERT & BOEHMERT attorneys appointed as lecturers at the University of Bremen

16. October 2024/in News

BOEHMERT & BOEHMERT partner and attorney at law Rudolf Böckenholt, patent agent (Malaysia) and patent engineer Sok Tiang (Chloe) Tai as well as attorneys at law Melanie Müller and Malte Benedikt Windeler have been appointed lecturers/readers at the University of Bremen for the LLM-Master Program “Transnational Law” with effect for the winter semester 2024/2025.

/wp-content/uploads/2022/04/boehmert_logo.svg 0 0 Petra Hettenkofer /wp-content/uploads/2022/04/boehmert_logo.svg Petra Hettenkofer2024-10-16 14:44:312024-10-16 14:44:50Four BOEHMERT & BOEHMERT attorneys appointed as lecturers at the University of Bremen

Focus “Best Commercial Law Firms in Germany 2024”: BOEHMERT & BOEHMERT recognized again

10. October 2024/in Awards & Rankings

Above-average recommendations from clients in the patent law and trade mark law categories

In the new issue of “FOCUS Spezial Recht & Rat”, the business magazine once again ranks BOEHMERT & BOEHMERT among the best commercial law firms in Germany in 2024.

The law firm was listed for the legal fields of patent law and trade mark law. In both cases, the BOEHMERT & BOEHMERT teams received a disproportionately high recommendation from clients.

The annual list published by FOCUS Business names leading lawyers and commercial law firms from a total of 25 specialist areas. FOCUS develops the methodology for compiling the list of top lawyers together with the research institute FactField. Around 3,094 lawyers from commercial law firms and companies took part this year. 454 commercial law firms were recommended.

/wp-content/uploads/2022/04/boehmert_logo.svg 0 0 Petra Hettenkofer /wp-content/uploads/2022/04/boehmert_logo.svg Petra Hettenkofer2024-10-10 14:10:032024-10-21 14:14:37Focus “Best Commercial Law Firms in Germany 2024”: BOEHMERT & BOEHMERT recognized again

Latest posts

  • IP seminars in India – February 3 to 6, 2026, in three major cities15. January 2026 - 13:20
  • Prof. Dr. Heinz Goddar, Patent Attorney at BOEHMERT & BOEHMERT
    Prof. Dr. Goddar added to the list of mediators and members of the PMAC arbitration tribunal1. January 2026 - 8:00
  • Dr. Daniel Herrmann, Patent Attorney at BOEHMERT & BOEHMERT
    “Intellectual property rights have a significant impact on business” – Interview with Dr. Daniel Herrmann in the WiWo supplement 12/202516. December 2025 - 12:06

Categories

Archive

Menu

  • Firm
  • Our Practice
  • Career
  • News & Events
  • FIND EXPERTS
  • LinkedIn

Informations

  • Press
  • Contact
  • Legal notice
  • Data Protection
  • General Terms and Conditions
  • Contact

Legal Areas

  • Employee Inventions
  • Data Protection
  • Designs
  • Domains
  • Information Technology
  • Anti-Trust
  • Licensing
  • Trade Marks
  • Patent Valuation
  • Patents & Utility Models
  • Patent Litigation
  • Product Piracy
  • Copyright
  • Unfair Competition

© Copyright 2026– BOEHMERT & BOEHMERT

Scroll to top Scroll to top Scroll to top